Drug intelligence / Profile preview

MateRegen gel

Development stage: Unknown
Lead developer: BioRegen Biomedical
Administration: Intrauterine

Overview

MateRegen Gel is a cross-linked hyaluronic acid (Na-hyaluronate) gel medical device developed by BioRegen Biomedical Changzhou. It is a Class III medical device designed for the prevention of intrauterine adhesions (IUA) following intrauterine surgical procedures. The gel is prepared using a proprietary thiolated chemistry to create a self-cross-linked, non-animal-sourced hydrogel. It functions by physically isolating the uterine cavity walls during the critical 7–30 day healing period post-surgery, after which it is naturally degraded and absorbed. MateRegen has received CFDA approval in China, CE certification in Europe, and TGA registration in Australia, and is recognized in AAGL/ESGE treatment guidelines.

Brand names: MateRegen gel
Other names: MateRegen

Beyond the preview

Go deeper on MateRegen gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MateRegen gel.

Explore the full profile